Galenica Climbs After Raising 2012 Profit Forecast: Zurich Mover

Galenica AG (GALN), the world’s biggest maker of iron-replacement drugs, rose the most in more than nine months in Zurich after increasing its full-year profit forecast.

Galenica climbed as much as 4.5 percent, the biggest intraday advance since Nov. 11. The stock traded 3.9 percent higher at 581 Swiss francs as of 9:16 a.m. The shares have advanced 7.1 percent this year, including reinvested dividends, compared with a 12 percent gain in the Swiss Performance Index.

The Bern, Switzerland-based company expects profit to rise this year, it said as it reported first-half earnings today. Galenica said in March that 2012 profit would be unchanged.

First-half net income rose 13 percent to 119.6 million francs ($123 million), and sales advanced 2.2 percent to 1.62 billion francs.

To contact the reporter on this story: Simeon Bennett in Geneva at

To contact the editor responsible for this story: Kristen Hallam at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.